Martindale Pharma has announced the UK launch of Prenoxad injection, the licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.
Prenoxad Injection is a prescription only medicine (POM) that contains a solution of naloxone hydrochloride.
It is used for emergency for either complete or partial reversal of life-threatening respiratory depression which follows the administration of natural or synthetic opioids.
Martindale Pharma has developed Prenoxad Injection extensive consultation and networking with those responsible for commissioning and delivering outcome focused recovery orientated services.
Martindale Pharma CEO Richard de Souza said that more than 1,000 deaths occur each year in the UK as a result of opiate related overdoses and the introduction of Prenoxad Injection marks an important advance in supporting recovery programmes designed to reduce the number of avoidable deaths.